MINNEAPOLIS--(BUSINESS WIRE)--Urologix(R), Inc. (NASDAQ:ULGX) is proud to announce today their complete 5 year data from the prospective FDA IDE study of the CTC treatment catheter for the treatment of BPH. Dr. Claus Roehrborn, Professor and Chairman of University of Texas Southwestern Medical Center, Department of Urology, presented the data at the 2009 American Urological Association Annual Meeting.
